Nkarta, Inc. (NKTX)
- Previous Close
6.53 - Open
6.51 - Bid 6.74 x 100
- Ask 6.76 x 100
- Day's Range
6.44 - 6.83 - 52 Week Range
1.28 - 16.24 - Volume
219,999 - Avg. Volume
1,029,532 - Market Cap (intraday)
475.656M - Beta (5Y Monthly) 0.89
- PE Ratio (TTM)
-- - EPS (TTM)
-2.35 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
18.75
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
www.nkartatx.comRecent News: NKTX
Performance Overview: NKTX
Trailing total returns as of 5/20/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NKTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NKTX
Valuation Measures
Market Cap
460.15M
Enterprise Value
109.93M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.97
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-15.07%
Return on Equity (ttm)
-28.33%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-116.2M
Diluted EPS (ttm)
-2.35
Balance Sheet and Cash Flow
Total Cash (mrq)
437.39M
Total Debt/Equity (mrq)
18.41%
Levered Free Cash Flow (ttm)
-78.01M
Research Analysis: NKTX
Company Insights: NKTX
NKTX does not have Company Insights